A Phase II Investigator-Initiated Clinical Trial Evaluating the Safety and Efficacy of Pitavastatin in Myelofibrosis Patients Treated with JAK Inhibitors

未提供0 个研究点目标入组 24 人开始时间: 待定

适应症

试验速览

暂无简介。

•Patients with a confirmed diagnosis of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) according to the diagnostic criteria of the 2017 revised 4th edition of the WHO Classification or the 5th edition of the WHO Classification (2022).
•Patients who have been receiving a JAK inhibitor for at least 12 weeks at the time of enrollment for the treatment of myelofibrosis.
•Patients who demonstrate at least Grade 1 (MF-1) bone marrow fibrosis on a screening bone marrow biopsy, based on the bone marrow fibrosis grading system defined in the 2017 revised 4th edition of the WHO Classification.

•Patients who received HMG-CoA reductase inhibitors (statins) within the 12 weeks prior to the registration date following a diagnosis of myelofibrosis, and patients currently receiving HMG-CoA reductase inhibitors.
•Patients with hereditary muscle disorders (e.g., muscular dystrophy) or a family history of such disorders.
•Patients with a history of drug-induced myopathy.
•Patients with myasthenia gravis or a history of myasthenia gravis.

发起方

未提供